Resistance to Imatinib: Mutations and Beyond
Tóm tắt
Từ khóa
Tài liệu tham khảo
Druker, 2008, Translation of the Philadelphia chromosome into therapy for CML, Blood, 112, 4808, 10.1182/blood-2008-07-077958
Weisberg, 2007, Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia, Nat Rev Cancer, 7, 345, 10.1038/nrc2126
Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867
Hochhaus, 2009, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, 23, 1054, 10.1038/leu.2009.38
Hochhaus, 2008, Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment, Blood, 111, 1039, 10.1182/blood-2007-07-103523
Baccarani, 2009, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol, 27, 6041, 10.1200/JCO.2009.25.0779
Mahon, 2009, Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients, Blood, 114, 353a, 10.1182/blood.V114.22.859.859
Hochhaus, 2002, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy, Leukemia, 16, 2190, 10.1038/sj.leu.2402741
Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538
La Rosee, 2008, Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib, Haematologica, 93, 765, 10.3324/haematol.12186
Schindler, 2000, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase, Science, 289, 1938, 10.1126/science.289.5486.1938
Wisniewski, 2002, Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases, Cancer Res, 62, 4244
O'Hare, 2005, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants, Cancer Res, 65, 4500, 10.1158/0008-5472.CAN-05-0259
Laneuville, 2010, Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia, J Clin Oncol, 28, e169, 10.1200/JCO.2009.26.4945
Muller, 2009, Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations, Blood, 114, 4944, 10.1182/blood-2009-04-214221
Hughes, 2009, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase, J Clin Oncol, 27, 4204, 10.1200/JCO.2009.21.8230
Talpaz, 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias, N Engl J Med, 354, 2531, 10.1056/NEJMoa055229
Jabbour, 2010, Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history, Leukemia, 24, 6, 10.1038/leu.2009.193
Soverini, 2009, Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors, Blood, 114, 2168, 10.1182/blood-2009-01-197186
Shah, 2007, Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency, J Clin Invest, 117, 2562, 10.1172/JCI30890
O'Hare, 2009, AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance, Cancer Cell, 16, 401, 10.1016/j.ccr.2009.09.028
Nagar, 2002, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571), Cancer Res, 62, 4236
Azam, 2008, Activation of tyrosine kinases by mutation of the gatekeeper threonine, Nat Struct Mol Biol, 15, 1109, 10.1038/nsmb.1486
Skaggs, 2006, Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants, Proc Natl Acad Sci U S A, 103, 19466, 10.1073/pnas.0609239103
Griswold, 2006, Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib, Mol Cell Biol, 26, 6082, 10.1128/MCB.02202-05
Nicolini, 2009, Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation, Blood, 114, 5271, 10.1182/blood-2009-04-219410
Branford, 2003, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis, Blood, 102, 276, 10.1182/blood-2002-09-2896
Stoklosa, 2008, BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations, Cancer Res, 68, 2576, 10.1158/0008-5472.CAN-07-6858
Koptyra, 2008, BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress, Leukemia, 22, 1969, 10.1038/leu.2008.78
Fernandes, 2009, BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair, Blood, 114, 1813, 10.1182/blood-2008-07-172148
Chu, 2004, BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells, Blood, 103, 3167, 10.1182/blood-2003-04-1271
Copland, 2006, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction, Blood, 107, 4532, 10.1182/blood-2005-07-2947
Konig, 2008, Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells, Cancer Res, 68, 9624, 10.1158/0008-5472.CAN-08-1131
Konig, 2008, Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606, Blood, 111, 2329, 10.1182/blood-2007-05-092056
Konig, 2008, Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors, Leukemia, 22, 748, 10.1038/sj.leu.2405086
Chu, 2005, Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment, Blood, 105, 2093, 10.1182/blood-2004-03-1114
Jiang, 2007, Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies, Leukemia, 21, 926, 10.1038/sj.leu.2404609
Graham, 2002, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro, Blood, 99, 319, 10.1182/blood.V99.1.319
La Rosée, 2003, No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec), Hematol J, 4, 413, 10.1038/sj.thj.6200297
Jamieson, 2008, Chronic myeloid leukemia stem cells, Hematol Am Soc Hematol Educ Program, 436, 10.1182/asheducation-2008.1.436
Burchert, 2005, Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development, Leukemia, 19, 1774, 10.1038/sj.leu.2403898
Wang, 2007, Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation, Blood, 109, 2147, 10.1182/blood-2006-08-040022
Weisberg, 2008, Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells, Mol Cancer Ther, 7, 1121, 10.1158/1535-7163.MCT-07-2331
Mackenzie, 2009, Defining extrinsic survival pathways in CML progenitor cells, Blood, 114, 388a, 10.1182/blood.V114.22.941.941
Lemoli, 2009, Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib, Blood, 114, 5191, 10.1182/blood-2008-08-176016
Jamieson, 2004, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML, N Engl J Med, 351, 657, 10.1056/NEJMoa040258
Abrahamsson, 2009, Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation, Proc Natl Acad Sci U S A, 106, 3925, 10.1073/pnas.0900189106
Coluccia, 2007, Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation, EMBO J, 26, 1456, 10.1038/sj.emboj.7601485
Zhao, 2007, Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo, Cancer Cell, 12, 528, 10.1016/j.ccr.2007.11.003
Zhao, 2009, Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia, Nature, 458, 776, 10.1038/nature07737
Dierks, 2008, Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation, Cancer Cell, 14, 238, 10.1016/j.ccr.2008.08.003
Essers, 2009, IFNalpha activates dormant haematopoietic stem cells in vivo, Nature, 458, 904, 10.1038/nature07815
Crossman, 2005, In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures, Haematologica, 90, 459
Radich, 2006, Gene expression changes associated with progression and response in chronic myeloid leukemia, Proc Natl Acad Sci U S A, 103, 2794, 10.1073/pnas.0510423103
McWeeney, 2010, A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic phase chronic myeloid leukemia patients treated with imatinib, Blood, 115, 315, 10.1182/blood-2009-03-210732
Apperley, 2007, Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia, Lancet Oncol, 8, 1018, 10.1016/S1470-2045(07)70342-X
Dulucq, 2008, Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 112, 2024, 10.1182/blood-2008-03-147744
Kim, 2009, Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia, Clin Cancer Res, 15, 4750, 10.1158/1078-0432.CCR-09-0145
Hatziieremia, 2009, Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34(+) cells to imatinib, Exp Hematol, 37, 692, 10.1016/j.exphem.2009.02.006
Shah, 2008, Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia, J Clin Oncol, 26, 3204, 10.1200/JCO.2007.14.9260
Shah, 2008, Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis, Cancer Cell, 14, 485, 10.1016/j.ccr.2008.11.001
Snead, 2009, Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis, Blood, 114, 3459, 10.1182/blood-2007-10-113969
Hiwase, 2009, Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells, Leukemia, 23, 1205, 10.1038/leu.2009.45
Picard, 2007, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, 109, 3496, 10.1182/blood-2006-07-036012
Larson, 2008, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, 111, 4022, 10.1182/blood-2007-10-116475
Wu, 2010, Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients, Curr Med Res Opin, 26, 61, 10.1185/03007990903396469
Noens, 2009, Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, 113, 5401, 10.1182/blood-2008-12-196543
Rosti, 2009, Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia, Blood, 114, 4933, 10.1182/blood-2009-07-232595
Cortes, 2009, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia, J Clin Oncol, 28, 398, 10.1200/JCO.2009.25.4920
Saglio, 2009, Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the International Randomized Phase III ENESTnd Trial, Blood, 10.1182/blood.V114.22.LBA-1.LBA-1